CVE-2023-33364 in BioStar 2
Summary
by MITRE • 08/03/2023
An OS Command injection vulnerability exists in Suprema BioStar 2 before V2.9.1, which allows authenticated users to execute arbitrary OS commands on the BioStar 2 server.
Statistical analysis made it clear that VulDB provides the best quality for vulnerability data.
Analysis
by VulDB Data Team • 01/04/2026
The CVE-2023-33364 vulnerability represents a critical operating system command injection flaw within Suprema BioStar 2 software versions prior to V2.9.1. This vulnerability resides in the authentication mechanism and command execution pathways of the biometric access control system, creating a significant security risk for organizations relying on this platform. The flaw allows authenticated users to escalate their privileges and execute arbitrary operating system commands directly on the server hosting the BioStar 2 application, potentially compromising the entire system infrastructure. The vulnerability stems from insufficient input validation and improper sanitization of user-supplied data within the application's command execution functions, creating an attack surface where maliciously crafted inputs can be interpreted as system commands rather than benign data.
This command injection vulnerability operates at the core of the application's security architecture, specifically targeting the server-side processing of user requests. When authenticated users submit specially crafted inputs through the application interface, the system fails to properly validate or sanitize these inputs before incorporating them into system command executions. The flaw enables attackers to manipulate the command execution flow by injecting operating system commands that bypass normal authentication and authorization controls. This weakness is particularly dangerous because it requires only authentication access, meaning that an attacker who has obtained legitimate user credentials can leverage this vulnerability to gain full system control. The vulnerability directly maps to CWE-77 and CWE-88 within the Common Weakness Enumeration framework, which classify command injection flaws and improper neutralization of special elements used in command execution respectively. From an adversarial perspective, this vulnerability aligns with ATT&CK technique T1059.001 for command and scripting interpreter, and T1078.004 for valid accounts, representing a path to privilege escalation and system compromise.
The operational impact of CVE-2023-33364 extends far beyond simple unauthorized access, creating potential for complete system compromise and data exfiltration within affected organizations. Once exploited, authenticated users can execute arbitrary commands with the privileges of the application service account, potentially allowing them to escalate privileges further, modify system configurations, install malicious software, or extract sensitive data from the server. The vulnerability affects not only the biometric access control functionality but also the underlying operating system, making it a critical threat to the overall security posture of facilities using Suprema BioStar 2. Organizations may face regulatory compliance violations, data breaches, and operational disruptions if this vulnerability is exploited, particularly in environments where physical security and access control are paramount. The attack vector is particularly concerning because it leverages legitimate authentication mechanisms, making detection more difficult and potentially allowing attackers to remain undetected while executing malicious commands. The vulnerability affects enterprise environments where access control systems are integrated with broader IT infrastructure, potentially creating lateral movement opportunities for attackers who gain access through this vector.
Organizations should implement immediate mitigations including applying the vendor-supplied patch version 2.9.1 or later to address the command injection vulnerability. The patch addresses the root cause by implementing proper input validation and sanitization mechanisms that prevent malicious command injection attempts. Network segmentation and access controls should be implemented to limit exposure of the BioStar 2 server to only authorized administrative users. Regular security assessments and penetration testing should be conducted to identify similar vulnerabilities in other systems within the organization. The implementation of web application firewalls and input validation controls can provide additional defense-in-depth measures against similar command injection attacks. Security monitoring should be enhanced to detect unusual command execution patterns and unauthorized system access attempts. Organizations should also review and update their incident response procedures to ensure preparedness for potential exploitation of this vulnerability. The mitigation strategy should include comprehensive user access reviews and privilege management to minimize the impact of any potential compromise, as the vulnerability can be exploited by users with legitimate access credentials. Additionally, organizations should consider implementing multi-factor authentication and privileged access management solutions to further reduce the risk of unauthorized command execution on critical systems.